Cocrystal Pharma, INC

Cocrystal Pharma announced a $5 million private placement with existing investor OPKO Health, Inc., to advance its antiviral drug candidate programs.

Cocrystal Pharma, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of five directors and ratification of its independent auditor.

Cocrystal Pharma, Inc. announced the immediate appointment of James Sapirstein as Chief Executive Officer, effective June 3, 2026, alongside a new stock option grant.

Cocrystal Pharma has appointed James Sapirstein as its new Chief Executive Officer, effective immediately, leveraging his extensive antiviral development experience.

Cocrystal Pharma announces the discovery of novel direct-acting antivirals demonstrating pan-viral activity against hantavirus, bunyavirus, and influenza.

Cocrystal Pharma presented positive Phase 1 data and clinical advancement for its oral norovirus candidate, CDI-988, at ICAR 2026.

Cocrystal Pharma reported a net loss of $2.3 million for Q1 2026, with cash reserves projected to last less than 12 months, while advancing its antiviral drug candidates.

Cocrystal Pharma reported reduced net losses and R&D expenses while advancing its influenza and norovirus/coronavirus programs, but faces substantial doubt about its ability to continue as a going concern.

Cocrystal Pharma reported significant net losses and declining cash, raising substantial doubt about its ability to continue as a going concern, despite progress in antiviral drug development.

Cocrystal Pharma's Q1 2025 results show a reduced net loss compared to the previous year, driven by decreased research and development expenses, but the company expresses concerns about its ability to continue as a going concern without additional funding.

Cocrystal Pharma reported a net loss of $4.939 million for the third quarter of 2024, while continuing to advance its antiviral drug development programs.

Cocrystal Pharma reported a net loss of $9.3 million for the first half of 2024, while advancing its antiviral drug candidates through clinical trials.

Cocrystal Pharma's annual report highlights significant financial challenges, including a going concern doubt and a failed Phase 2a influenza trial, despite progress in other antiviral programs.

Cocrystal Pharma's annual report reveals ongoing antiviral therapeutic development efforts alongside financial challenges and a going concern qualification.

Cocrystal Pharma has filed an amendment to its annual report to include information required in Part III, which was not included in the original filing.

Cocrystal Pharma has formalized its ethical standards and insider trading rules with the adoption of a new Code of Ethics and Insider Trading Policy.

Cocrystal Pharma, Inc. reports the grant of stock options to CEO James Sapirstein under the 2025 Equity Incentive Plan.

Cocrystal Pharma Director Phillip Frost, MD, increased his indirect beneficial ownership by purchasing 20,000 shares of common stock.

Phillip Frost, a Director and 10% owner of Cocrystal Pharma, disclosed a planned acquisition of 50,000 common shares under a Rule 10b5-1 plan.

Cocrystal Pharma Director Roger D. Kornberg received a grant of 24,615 non-qualified stock options with an exercise price of $1.10.

Cocrystal Pharma's Director, Richard C. Pfenniger Jr., was granted 16,410 non-qualified stock options with an exercise price of $1.1 under the 2025 Equity Incentive Plan.

Cocrystal Pharma's President and Co-CEO, Sam Lee, was granted 49,229 non-qualified stock options with an exercise price of $1.1, vesting over time.

Cocrystal Pharma, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on July 14, 2026, to elect directors, ratify auditors, and address potential meeting adjournments.

Cocrystal Pharma will hold its 2025 annual meeting of stockholders virtually on June 25, 2025, to vote on the election of directors, ratification of the company's accounting firm, approval of the 2025 Equity Incentive Plan, and a potential adjournment.

Cocrystal Pharma is holding its 2025 Annual Meeting of Stockholders virtually on June 25, 2025, to vote on key proposals including the election of directors, ratification of the independent auditor, and approval of a new equity incentive plan.

Cocrystal Pharma is holding its 2024 Annual Meeting of Stockholders virtually on June 25, 2024, to vote on key proposals including director elections, auditor ratification, and amendments to the Certificate of Incorporation.

Cocrystal Pharma files S-1 to register 5.7 million shares for resale by selling stockholders, while disclosing substantial doubt about its ability to continue as a going concern.

Phillip Frost, M.D. and Frost Gamma Investments Trust increased their beneficial ownership in Cocrystal Pharma, Inc. through a recent unit purchase.

Phillip Frost, M.D. and Frost Gamma Investments Trust reported an increased beneficial ownership in Cocrystal Pharma, Inc. to 10.6% following RSU vesting.